Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$286.17
+0.3%
$265.60
$190.75
▼
$291.40
$505.62B0.246.36 million shs2.07 million shs
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$103.25
+0.7%
$105.30
$81.97
▼
$132.02
$178.90B0.5911.29 million shs3.13 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,268.65
-2.9%
$1,184.78
$809.63
▼
$1,321.21
$1.20T0.462.93 million shs986,426 shs
Lincoln National Corporation stock logo
LNC
Lincoln National
$39.46
-4.0%
$42.17
$32.18
▼
$47.67
$7.53B1.162.02 million shs683,365 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$145.10
-1.5%
$146.79
$82.01
▼
$156.92
$357.33B0.2110.64 million shs4.39 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$30.04
-1.3%
$28.26
$23.62
▼
$30.44
$171.28B0.3239.79 million shs14.15 million shs
Phillips 66 stock logo
PSX
Phillips 66
$284.26
-0.1%
$261.89
$127.16
▼
$299.39
$113.40B0.712.83 million shs1.29 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.02%+0.54%+7.23%+9.84%+24.51%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+2.04%-2.05%-1.04%-0.47%-19.70%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+2.86%+4.33%+11.71%+9.37%+61.04%
Lincoln National Corporation stock logo
LNC
Lincoln National
+1.63%+2.61%-0.12%-0.75%+3.91%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-1.72%+1.20%-2.39%+12.47%+68.27%
Pfizer Inc. stock logo
PFE
Pfizer
+1.74%+3.16%+8.87%+23.93%+22.98%
Phillips 66 stock logo
PSX
Phillips 66
-2.15%-1.80%+10.59%+37.30%+116.51%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$286.17
+0.3%
$265.60
$190.75
▼
$291.40
$505.62B0.246.36 million shs2.07 million shs
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$103.25
+0.7%
$105.30
$81.97
▼
$132.02
$178.90B0.5911.29 million shs3.13 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,268.65
-2.9%
$1,184.78
$809.63
▼
$1,321.21
$1.20T0.462.93 million shs986,426 shs
Lincoln National Corporation stock logo
LNC
Lincoln National
$39.46
-4.0%
$42.17
$32.18
▼
$47.67
$7.53B1.162.02 million shs683,365 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$145.10
-1.5%
$146.79
$82.01
▼
$156.92
$357.33B0.2110.64 million shs4.39 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$30.04
-1.3%
$28.26
$23.62
▼
$30.44
$171.28B0.3239.79 million shs14.15 million shs
Phillips 66 stock logo
PSX
Phillips 66
$284.26
-0.1%
$261.89
$127.16
▼
$299.39
$113.40B0.712.83 million shs1.29 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.02%+0.54%+7.23%+9.84%+24.51%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+2.04%-2.05%-1.04%-0.47%-19.70%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+2.86%+4.33%+11.71%+9.37%+61.04%
Lincoln National Corporation stock logo
LNC
Lincoln National
+1.63%+2.61%-0.12%-0.75%+3.91%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-1.72%+1.20%-2.39%+12.47%+68.27%
Pfizer Inc. stock logo
PFE
Pfizer
+1.74%+3.16%+8.87%+23.93%+22.98%
Phillips 66 stock logo
PSX
Phillips 66
-2.15%-1.80%+10.59%+37.30%+116.51%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.83
Moderate Buy$279.86-2.21% Downside
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.93
Moderate Buy$118.3214.60% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.86
Moderate Buy$1,317.933.88% Upside
Lincoln National Corporation stock logo
LNC
Lincoln National
2.46
Hold$48.6723.34% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.59
Moderate Buy$151.924.70% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.14
Hold$28.72-4.37% Downside
Phillips 66 stock logo
PSX
Phillips 66
2.75
Moderate Buy$269.88-5.06% Downside

Current Analyst Ratings Breakdown

Latest LNC, ABBV, ABT, LLY, PFE, MRK, and PSX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/23/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Reiterated RatingNeutral$294.00
10/22/2026
Phillips 66 stock logo
PSX
Phillips 66
Boost Price TargetBuy$295.00 ➝ $308.00
10/22/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Lower Price TargetBuy$125.00 ➝ $122.00
10/22/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Lower Price TargetOutperform$130.00 ➝ $125.00
10/22/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Boost Price TargetOverweight$112.00 ➝ $119.00
10/22/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Lower Price TargetOverweight$120.00 ➝ $118.00
10/22/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Lower Price TargetBuy$135.00 ➝ $118.00
10/22/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Lower Price TargetBuy$134.00 ➝ $125.00
10/22/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Boost Price TargetOutperform$121.00 ➝ $123.00
10/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOutperform$1,309.00 ➝ $1,316.00
10/21/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetOverweight$300.00 ➝ $325.00
(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B8.27$15.22 per share18.80($1.83) per share-156.38
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$44.33B4.03$7.18 per share14.38$30.35 per share3.40
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B18.32$25.10 per share50.55$28.07 per share45.20
Lincoln National Corporation stock logo
LNC
Lincoln National
$18.21B0.41$8.38 per share4.71$52.23 per share0.76
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.51$11.06 per share13.12$21.22 per share6.84
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.74$4.42 per share6.79$15.26 per share1.97
Phillips 66 stock logo
PSX
Phillips 66
$136.56B0.83$14.42 per share19.71$75.05 per share3.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$3.5480.8417.821.309.80%-422.07%14.34%10/30/2026 (Estimated)
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$6.52B$3.0933.4616.981.869.75%17.97%9.22%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$29.8042.6026.891.6933.53%97.83%23.23%10/29/2026 (Estimated)
Lincoln National Corporation stock logo
LNC
Lincoln National
$1.18B$11.543.414.561.3612.21%17.35%0.41%11/5/2026 (Confirmed)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$1.25115.8715.656.924.77%16.73%6.13%10/29/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7639.5410.182.036.80%19.63%8.46%11/3/2026 (Estimated)
Phillips 66 stock logo
PSX
Phillips 66
$4.40B$17.5516.198.930.174.54%19.93%7.62%10/28/2026 (Estimated)

Latest LNC, ABBV, ABT, LLY, PFE, MRK, and PSX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Lincoln National Corporation stock logo
LNC
Lincoln National
$1.96N/AN/AN/A$4.97 billionN/A
11/3/2026Q3 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7280N/AN/AN/A$15.86 billionN/A
10/30/2026Q3 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.74N/AN/AN/A$17.36 billionN/A
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.70N/AN/AN/A$22.58 billionN/A
10/29/2026Q3 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.09N/AN/AN/A$17.31 billionN/A
10/28/2026Q3 2026
Phillips 66 stock logo
PSX
Phillips 66
$11.73N/AN/AN/A$44.87 billionN/A
10/21/2026Q3 2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.42$1.42N/A$0.53$12.99 billion$13.01 billion
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.40$8.38+$1.98$7.94$20.82 billion$22.97 billion
8/5/2026Q2 2026
Phillips 66 stock logo
PSX
Phillips 66
$7.50$9.41+$1.91$9.55$43.60 billion$51.00 billion
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.26-$0.13+$0.13-$0.54$16.37 billion$16.61 billion
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.43%+6.80%195.48%53 Years
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.522.46%+10.39%81.55%54 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.53%+15.18%23.22%11 Years
Lincoln National Corporation stock logo
LNC
Lincoln National
$1.804.39%+2.38%15.60%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.31%+5.75%272.00%14 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.725.66%-13.20%226.32%16 Years
Phillips 66 stock logo
PSX
Phillips 66
$5.081.79%+5.70%28.95%14 Years

Latest LNC, ABBV, ABT, LLY, PFE, MRK, and PSX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.26%11/6/202611/6/202612/7/2026
10/16/2026
Phillips 66 stock logo
PSX
Phillips 66
quarterly$1.331.81%11/17/202611/17/202612/1/2026
9/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.44%10/15/202610/15/202611/16/2026
9/17/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.632.4%10/15/202610/15/202611/16/2026
8/7/2026
Lincoln National Corporation stock logo
LNC
Lincoln National
quarterly$0.454.47%10/9/202610/12/202611/2/2026
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.36%9/15/20269/15/202610/7/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.81
0.69
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.57
1.38
0.97
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.41
1.35
1.00
Lincoln National Corporation stock logo
LNC
Lincoln National
0.62
0.27
0.27
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.22
1.32
1.10
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96
Phillips 66 stock logo
PSX
Phillips 66
0.57
1.32
1.00

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Lincoln National Corporation stock logo
LNC
Lincoln National
72.81%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Phillips 66 stock logo
PSX
Phillips 66
76.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
115,0001.73 billion1.72 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.36 million940.04 millionOptionable
Lincoln National Corporation stock logo
LNC
Lincoln National
9,423191.45 million189.48 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
Phillips 66 stock logo
PSX
Phillips 66
12,600399.02 million397.43 millionOptionable

Recent News About These Companies

Phillips 66 (PSX) Raises Quarterly Dividend To $1.33 Per Share
Phillips 66 (NYSE:PSX) Hits a Fresh High: What’s Fueling It?
Phillips 66 (PSX) Is Up 5.39% in One Week: What You Should Know
Phillips 66 (PSX) Projected to Release Earnings on Wednesday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$286.17 +0.98 (+0.34%)
As of 01:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$103.25 +0.74 (+0.72%)
As of 01:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,268.65 -38.04 (-2.91%)
As of 01:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Lincoln National stock logo

Lincoln National NYSE:LNC

$39.46 -1.65 (-4.02%)
As of 01:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Lincoln National Corporation, through its subsidiaries, operates multiple insurance and retirement businesses in the United States. It operates in four segments: Life Insurance, Annuities, Group Protection, and Retirement Plan Services. The Life Insurance segment provides life insurance products, including term insurance, universal life insurance (UL), indexed universal life insurance, variable universal life insurance (VUL), linked-benefit UL and VUL products, and critical illness and long-term care riders. The Annuities segment offers variable, fixed, and registered index-linked annuities. The Group Protection segment offers group non-medical insurance products consisting of short and long-term disability and statutory disability; paid family medical leave administration and absence management services; term life; dental and vision; and accident, critical illness, and hospital indemnity benefits and services to the employer marketplace through various forms of employee-paid and employer-paid plans. The Retirement Plan Services segment provides employers with retirement plan products and services primarily in the defined contribution retirement plan marketplace; individual and group variable annuities, group fixed annuities, and mutual fund-based programs; and various plan services, including plan recordkeeping, compliance testing, participant education, and trust and custodial services. The company distributes its products through consultants, brokers, planners, agents, financial advisors, third-party administrators, and other intermediaries. Lincoln National Corporation was founded in 1905 and is headquartered in Radnor, Pennsylvania.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$145.10 -2.15 (-1.46%)
As of 01:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer stock logo

Pfizer NYSE:PFE

$30.04 -0.39 (-1.27%)
As of 01:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Phillips 66 stock logo

Phillips 66 NYSE:PSX

$284.26 -0.38 (-0.13%)
As of 01:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Phillips 66 operates as an energy manufacturing and logistics company in the United States, the United Kingdom, Germany, and internationally. It operates through four segments: Midstream, Chemicals, Refining, and Marketing and Specialties (M&S). The Midstream segment transports crude oil and other feedstocks; delivers refined petroleum products to market; provides terminaling and storage services for crude oil and refined petroleum products; transports, stores, fractionates, exports, and markets natural gas liquids; provides other fee-based processing services; and gathers, processes, transports, and markets natural gas. The Chemicals segment produces and markets ethylene and other olefin products; aromatics and styrenics products, such as benzene, cyclohexane, styrene, and polystyrene; and various specialty chemical products, including organosulfur chemicals, solvents, catalysts, and chemicals used in drilling and mining. The Refining segment refines crude oil and other feedstocks into petroleum products, such as gasolines, distillates, aviation, and renewable. The M&S segment purchases for resale and markets refined petroleum products, including gasolines, distillates, and aviation fuels. This segment also manufactures and markets specialty products, such as base oils and lubricants. Phillips 66 was founded in 1875 and is headquartered in Houston, Texas.